Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
The objective is to investigate the efficacy and safety of envafolimab combined with chemotherapy for preoperative neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma
Esophageal Squamous Cell Carcinoma
DRUG: Envafolimab|DRUG: Albumin-Bound Paclitaxel|DRUG: Carboplatin
Rate of pCR, Rate of pathological complete remission, From Baseline to primary completion date, about 6 months
Rate of MPR, Rate of major pathological remission, From Baseline to primary completion date, about 6 months
Rate of SAE, Rate of severity Adverse Event, From Baseline to primary completion date, about 18 months
This study is a single-arm, exploratory phase II clinical study. In the study, all patients with esophageal squamous cell carcinoma who meet the inclusion criteria will receive 3 cycles (21 days of 1 cycle) of neoadjuvant envolizumab combined with chemotherapy Treatment, radical surgery 4-6 weeks after completion of the last neoadjuvant therapy.